{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T09:59:02Z","timestamp":1772531942946,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007825","name":"ACVIM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Veterinary Cardiology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jvc.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T11:42:50Z","timestamp":1622893370000},"page":"105-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Phase I clinical trial of an antithrombotic drug protocol combining apixaban and clopidogrel in dogs"],"prefix":"10.1016","volume":"36","author":[{"given":"A.L.","family":"Gagnon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.A.","family":"Scansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Olver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shropshire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Hess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.C.","family":"Orton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvc.2021.05.010_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1476-4431.2012.00824.x","article-title":"Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia","volume":"23","author":"Kidd","year":"2013","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2021.05.010_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/vec.12527","article-title":"Aortic thrombosis in dogs","volume":"27","author":"Williams","year":"2017","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2021.05.010_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jvc.2012.02.008","article-title":"Aortic thrombosis in dogs: presentation, therapy, and outcome in 26 cases","volume":"14","author":"Winter","year":"2012","journal-title":"J Vet Cardiol"},{"key":"10.1016\/j.jvc.2021.05.010_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.tcam.2012.08.002","article-title":"Antithrombotic therapy","volume":"27","author":"Smith","year":"2012","journal-title":"Top Companion Anim Med"},{"key":"10.1016\/j.jvc.2021.05.010_bib5","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jvc.2021.05.010_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1160\/TH10-10-0683","article-title":"Venous and arterial thrombosis\u2013pathogenesis and the rationale for anticoagulation","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvc.2021.05.010_bib7","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1161\/CIRCULATIONAHA.120.046448","article-title":"Compass investigators. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial","volume":"141","author":"Bhatt","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jvc.2021.05.010_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ehjcvp\/pvv014","article-title":"Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel","volume":"1","author":"Rohla","year":"2015","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jvc.2021.05.010_bib9","first-page":"15","article-title":"Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome","volume":"7","author":"Okuma","year":"2009","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.jvc.2021.05.010_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15420\/ecr.2019.10","article-title":"Antithrombotic therapy after transcatheter aortic valve implantation","volume":"15","author":"Lugo","year":"2020","journal-title":"Eur Cardiol"},{"key":"10.1016\/j.jvc.2021.05.010_bib11","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.jcin.2019.07.055","article-title":"Thrombotic risk and antithrombotic strategies after transcatheter mitral valve replacement","volume":"12","author":"Pagnesi","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jvc.2021.05.010_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/ATVBAHA.107.139402","article-title":"Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases","volume":"27","author":"Turpie","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jvc.2021.05.010_bib13","doi-asserted-by":"crossref","first-page":"640723","DOI":"10.1155\/2013\/640723","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","volume":"2013","author":"Gomez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.jvc.2021.05.010_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Editor's choice \u2013 efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvc.2021.05.010_bib15","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.amjcard.2017.07.092","article-title":"Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation","volume":"120","author":"Hernandez","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvc.2021.05.010_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tvjl.2017.03.006","article-title":"Anticoagulant activity of oral rivaroxaban in healthy dogs","volume":"223","author":"Conversy","year":"2017","journal-title":"Vet J"},{"key":"10.1016\/j.jvc.2021.05.010_bib17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/vec.12480","article-title":"Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia","volume":"26","author":"Morassi","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2021.05.010_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/vec.12466","article-title":"The use of rivaroxaban for the treatment of thrombotic complications in four dogs","volume":"26","author":"Yang","year":"2016","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2021.05.010_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jvc.2021.05.010_bib20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1080\/03007995.2017.1374935","article-title":"Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data","volume":"33","author":"Kohsaka","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jvc.2021.05.010_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine\u00a0practice: a cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvc.2021.05.010_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144856","article-title":"Comparison of novel oral anticoagulants apixaban, dabigatran, edoxaban, rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systemic review\u00a0and network meta-analysis","volume":"10","author":"Cohen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jvc.2021.05.010_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s13318-011-0037-x","article-title":"Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor","volume":"36","author":"He","year":"2011","journal-title":"Eur J Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jvc.2021.05.010_bib24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2460\/ajvr.71.7.822","article-title":"Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs","volume":"71","author":"Brainard","year":"2010","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.jvc.2021.05.010_bib25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.jvc.2021.05.010_bib26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.jvc.2021.05.010_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvc.2021.05.010_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/vec.12142","article-title":"Systematic evaluation of evidence on veterinary viscoelastic testing part 2: sample acquisition and handling","volume":"24","author":"Flatland","year":"2014","journal-title":"J Vet Emerg Crit Care"},{"key":"10.1016\/j.jvc.2021.05.010_bib29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvc.2021.05.010_bib30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvc.2021.05.010_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.jvc.2021.05.010_bib32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jvc.2021.05.010_bib33","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jvim.15478","article-title":"Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time","volume":"33","author":"Bae","year":"2019","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jvc.2021.05.010_bib34","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1182\/blood.V122.21.4813.4813","article-title":"Monitoring novel anticoagulants dabigatran, rivaroxaban and apixaban by thromboelastography. Proof of Concept","volume":"122","author":"Artang","year":"2013","journal-title":"Blood"}],"container-title":["Journal of Veterinary Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273421000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1760273421000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T02:39:32Z","timestamp":1761705572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1760273421000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":34,"alternative-id":["S1760273421000758"],"URL":"https:\/\/doi.org\/10.1016\/j.jvc.2021.05.010","relation":{},"ISSN":["1760-2734"],"issn-type":[{"value":"1760-2734","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I clinical trial of an antithrombotic drug protocol combining apixaban and clopidogrel in dogs","name":"articletitle","label":"Article Title"},{"value":"Journal of Veterinary Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvc.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}